Related Experiment Video
Updated: May 9, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Evaluation of the REDUCtion of thrombus burdEn with Core Lab OcT assessmenT (REDUCE-CLOTT) study
Jason Galo1, Abhishek Chaturvedi1, Evan Shlofmitz2
1Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America.
Background:
Optical coherence tomography (OCT) allows for quantitative analysis of thrombus in coronary vessels. High post-percutaneous coronary intervention (PCI) thrombotic burden as identified by OCT, correlates with adverse angiographic and periprocedural clinical outcomes.
Objective:
To assess by OCT the amount of residual thrombus post-PCI without the use of cangrelor, representing the standard of care and the control group of the REDUCE-CLOTT (The REDUCtion of thrombus burdEn with cangreLor by OcT assessmenT) study.
Methods:
This was a single-arm observational study of patients who presented with acute coronary syndrome or stable angina with evidence of acute thrombus on baseline OCT evaluation of the target lesion. All patients received treatment with PCI plus standard of care medications, with repeat OCT assessment peri-procedurally after PCI. The primary endpoint was the assessment of residual thrombus on post-PCI OCT, quantified as the total thrombus area (TTA) - calculated by measuring the total prolapsed thrombus area (TPTA), defined as the difference between the outer and lumen contours, and adding any free-floating thrombus.
Results:
A total of 17 patients and 18 lesions were included. Most were male (70.9 %), hypertensive (58.8 %), and smokers (64.7 %). Unfractionated heparin was used in 94.1 % and bivalirudin in 5.8 % of cases. TTA was numerically reduced by 35.4 % (relative difference), from 0.48 mm2 to 0.31 mm2 (p = 0.17). TPTA numerically reduced by 37.5 % (relative difference), from 0.48 mm2 to 0.31 mm2 (p = 0.15).
Conclusions:
PCI plus standard-of-care medications was associated with numerically lower, but not statistically significant, acute reduction of thrombus burden as assessed by OCT post-PCI.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

